Science News
from research organizations

New treatment discovered to cure MRSA infection

November 13, 2013
Northeastern University
Recent work promises to overcome one of the leading public health threats of our time. In a groundbreaking study, the team presents a novel approach to treat and eliminate methicillin resistant Staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers. That is, until now.

Professor Kim Lewis and his team developed a novel approach for treating chronic infections, which account for more than 20,000 deaths in the U.S. each year.
Credit: Mary Knox Merrill

Recent work from Uni­ver­sity Dis­tin­guished Pro­fessor of Biology Kim Lewis promises to over­come one of the leading public health threats of our time. In a ground­breaking study pub­lished today in the journal Nature, Lewis' team presents a novel approach to treat and elim­i­nate methi­cillin resis­tant staphy­lo­coccus aureus, or MRSA, a potent bac­terium whose resis­tance to antibi­otics has kept it one step ahead of researchers. That is, until now.

The so-​​called "superbug" infects 1 mil­lion Amer­i­cans each year. A major problem with MRSA is the devel­op­ment of deep-​​seated chronic infec­tions such as osteomyelitis (bone infec­tion), endo­carditis (heart infec­tion), or infec­tions of implanted med­ical devices. Once estab­lished, these infec­tions are often incur­able, even when appro­priate antibi­otics are used.

Bac­teria such as MRSA have evolved to actively resist cer­tain antibi­otics, a fact that has gen­er­ated sig­nif­i­cant interest among the sci­en­tific and med­ical com­mu­ni­ties. But Lewis, Director of Northeastern's Antimi­cro­bial Dis­covery Center, sus­pected that a dif­ferent adap­tive func­tion of bac­teria might be the true cul­prit in making these infec­tions so devastating.

The new work rep­re­sents the cul­mi­na­tion of more than a decade of research on a spe­cial­ized class of cells pro­duced by all pathogens called per­sis­ters. According to Lewis, these cells evolved to sur­vive. "Sur­vival is their only func­tion," he said. "They don't do any­thing else."

Lewis and his research team posited that if they could kill these expert sur­vivors, per­haps they could cure chronic infections -- even those resis­tant to mul­tiple antibi­otics such as MRSA. Fur­ther­more, said Brian Conlon, a post­doc­toral researcher in Lewis' lab and first author on the paper, "if you can erad­i­cate the per­sis­ters, there's less of a chance that resis­tance will develop at all."

Lewis, who was elected to the Amer­ican Academy of Micro­bi­ology in 2011 for his schol­ar­ship in the field, has found that per­sis­ters achieve their sin­gular goal by entering a dor­mant state that makes them imper­vious to tra­di­tional antibi­otics. Since these drugs work by tar­geting active cel­lular func­tions, they are use­less against dor­mant per­sis­ters, which aren't active at all. For this reason, per­sis­ters are crit­ical to the suc­cess of chronic infec­tions and biofilms, because as soon as a treat­ment runs its course, their reawak­ening allows for the infec­tion to estab­lish itself anew.

In the recent study, which also includes con­tri­bu­tions from assis­tant pro­fessor Steve Leonard of the Depart­ment of Phar­macy Prac­tice, Lewis' team found that a drug called ADEP effec­tively wakes up the dor­mant cells and then ini­ti­ates a self-​​destruct mech­a­nism. The approach com­pletely erad­i­cated MRSA cells in a variety of lab­o­ra­tory exper­i­ments and, impor­tantly, in a mouse model of chronic MRSA infection.

Cou­pling ADEP with a tra­di­tional antibi­otic, Conlon noted, allowed the team to com­pletely destroy the bac­te­rial pop­u­la­tion without leaving any survivors.

As with all other antibi­otics, actively growing bac­te­rial cells will likely develop resis­tance to ADEP. How­ever, Lewis said, "cells that develop ADEP resis­tance become rather wimpy." That is, other tra­di­tional drugs such as rifampicin or line­zolid work well against ADEP-​​resistant cells, pro­viding a unique cock­tail that not only kills per­sis­ters but also elim­i­nates ADEP-​​resistant mutant bacteria.

Dr. Richard Novick of New York University's Lan­gone Med­ical Center and a leader in the field said the research is a "bril­liant out­growth of Kim Lewis' pio­neering work on bac­te­rial per­sis­ters and rep­re­sents a highly cre­ative ini­tia­tive in this era of dimin­ishing antibi­otic utility."

While ADEP tar­gets MRSA, Lewis' team believes sim­ilar com­pounds will be useful for treating other infec­tions as well as any other dis­ease model that can only be over­come by elim­i­nating a pop­u­la­tion of rogue cells, including can­cerous tumors. They are pur­suing sev­eral already.

Story Source:

The above post is reprinted from materials provided by Northeastern University. Note: Materials may be edited for content and length.

Journal Reference:

  1. B. P. Conlon, E. S. Nakayasu, L. E. Fleck, M. D. Lafleur, V. M. Isabella, K. Coleman, S. N. Leonard, R. D. Smith, J. N. Adkins & K. Lewis. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature, November 2013

Cite This Page:

Northeastern University. "New treatment discovered to cure MRSA infection." ScienceDaily. ScienceDaily, 13 November 2013. <>.
Northeastern University. (2013, November 13). New treatment discovered to cure MRSA infection. ScienceDaily. Retrieved November 29, 2015 from
Northeastern University. "New treatment discovered to cure MRSA infection." ScienceDaily. (accessed November 29, 2015).

Share This Page: